<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Neurol.</journal-id>
<journal-title>Frontiers in Neurology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Neurol.</abbrev-journal-title>
<issn pub-type="epub">1664-2295</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fneur.2023.1194456</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neurology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>The effect of vascular risk factors on the efficacy of endolymphatic sac decompression surgery for Meniere&#x2019;s disease: a retrospective cohort study</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Li</surname> <given-names>Yiling</given-names></name><xref rid="aff1" ref-type="aff"><sup>1</sup></xref><xref rid="aff2" ref-type="aff"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2259463/overview"/>
</contrib>
<contrib contrib-type="author"><name><surname>Gong</surname> <given-names>Fengyuan</given-names></name><xref rid="aff3" ref-type="aff"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author"><name><surname>Guo</surname> <given-names>Yangyang</given-names></name><xref rid="aff1" ref-type="aff"><sup>1</sup></xref><xref rid="aff2" ref-type="aff"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author"><name><surname>Xu</surname> <given-names>Xianrong</given-names></name><xref rid="aff2" ref-type="aff"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Wang</surname> <given-names>Cuicui</given-names></name><xref rid="aff2" ref-type="aff"><sup>2</sup></xref><xref rid="c002" ref-type="corresp"><sup>&#x002A;</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Jin</surname> <given-names>Zhanguo</given-names></name><xref rid="aff1" ref-type="aff"><sup>1</sup></xref><xref rid="aff2" ref-type="aff"><sup>2</sup></xref><xref rid="c001" ref-type="corresp">
<sup>&#x002A;</sup></xref>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Air Force Clinical College, The Fifth School of Clinical Medicine, Anhui Medical University</institution>, <addr-line>Hefei, Anhui</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Vertigo Clinic/Research Center of Aerospace Medicine, Air Force Medical Center, PLA</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff>
<aff id="aff3"><sup>3</sup><institution>Graduate School, Hebei North University</institution>, <addr-line>Zhangjiakou</addr-line>, <country>China</country></aff>
<author-notes>
<fn id="fn0001" fn-type="edited-by">
<p>Edited by: Lisheng Yu, Peking University People's Hospital, China</p>
</fn>
<fn id="fn0002" fn-type="edited-by">
<p>Reviewed by: Tadashi Kitahara, Nara Medical University, Japan; Entong Wang, Beijing Electric Power Hospital, China; Jing Wang, EENT Hospital, Fudan, China</p>
</fn>
<corresp id="c001">&#x002A;Correspondence: Zhanguo Jin, <email>ccjzg@126.com</email></corresp>
<corresp id="c002">Cuicui Wang, <email>cuicuiwang_169@163.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>25</day>
<month>05</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1194456</elocation-id>
<history>
<date date-type="received">
<day>27</day>
<month>03</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>09</day>
<month>05</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2023 Li, Gong, Guo, Xu, Wang and Jin.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Li, Gong, Guo, Xu, Wang and Jin</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Objectives</title>
<p>This study aimed to investigate the effect of vascular risk factors on the outcomes of endolymphatic sac decompression (ESD) surgery in patients with Meniere&#x2019;s disease.</p>
</sec>
<sec>
<title>Methods</title>
<p>The study included 56 patients with Meniere&#x2019;s disease, who had undergone unilateral ESD surgery. The patients&#x2019; vascular risk factors were assessed based on the preoperative 10-year atherosclerotic cardiovascular diseases risk classification. Those with no or low risk were defined as the low-risk group, while those with medium, high, or very high risk were defined as the high-risk group. The correlation between the vascular risk factors and ESD efficacy was evaluated by the comparison of vertigo control grade between the two groups. The functional disability score was also assessed to investigate whether ESD improved the quality of life in Meniere&#x2019;s disease patients with vascular risk factors.</p>
</sec>
<sec>
<title>Results</title>
<p>After ESD, 78.95 and 81.08% of patients from the low-risk and high-risk groups, respectively, demonstrated at least grade B vertigo control; no statistically significant difference was observed (<italic>p</italic>&#x2009;=&#x2009;0.96). The postoperative functional disability scores in both groups were significantly lower compared with those before surgery (<italic>p</italic>&#x2009;&#x003C;&#x2009;0.01), with a median decrease of two (1, 2) points in both groups. No statistically significant difference between the two groups was observed (<italic>p</italic>&#x2009;=&#x2009;0.65).</p>
</sec>
<sec>
<title>Conclusion</title>
<p>Vascular risk factors have little effect on the efficacy of ESD in patients with Meniere&#x2019;s disease. Patients with one or more vascular risk factors can still experience a not poor vertigo control and improved quality of life after ESD.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Meniere&#x2019;s disease</kwd>
<kwd>endolymphatic sac decompression</kwd>
<kwd>vascular risk factor</kwd>
<kwd>vertigo</kwd>
<kwd>quality of life</kwd>
</kwd-group>
<counts>
<fig-count count="1"/>
<table-count count="4"/>
<equation-count count="0"/>
<ref-count count="36"/>
<page-count count="7"/>
<word-count count="5018"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Neuro-Otology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="sec5" sec-type="intro">
<label>1.</label>
<title>Introduction</title>
<p>Meniere&#x2019;s disease (MD) is an inner ear disease characterized by paroxysmal vertigo, fluctuating hearing loss, tinnitus, and ear fullness (<xref ref-type="bibr" rid="ref1">1</xref>). The etiology of MD is unknown, and the main pathological feature is membranous labyrinthine hydrops which increased pressure in the inner ear, bringing vertigo attack, Reissner membrane displacement, and hair cell damage (<xref ref-type="bibr" rid="ref2">2</xref>). Vertigo control is the main demand of most MD patients while protection of hearing and vestibular function is also expected. For patients with frequent vertigo attacks and ineffective non-surgical treatment for 6&#x2009;months, surgical treatment can be performed (<xref ref-type="bibr" rid="ref3">3</xref>).</p>
<p>The surgical methods could be divided into two types according to whether the vestibular function was preserved. Vestibular function destructive surgeries such as semicircular canal occlusion control vertigo by damaging the vestibular sensory organ, while vestibular function protection surgeries such as endolymphatic sac decompression (ESD) do it by reducing the inner pressure. With the latter surgery, the audio-vestibular function is preserved to the maximum extent and the time and money spent on vestibular rehabilitation required due to surgical injury will be avoided. However, the application of ESD is limited by its uncertain curative effect (<xref ref-type="bibr" rid="ref4">4</xref>). Most of the studies reported a vertigo control rate of approximately 80% (<xref ref-type="bibr" rid="ref5">5</xref>), and some reported only 66% (<xref ref-type="bibr" rid="ref6">6</xref>) or even lower (<xref ref-type="bibr" rid="ref7">7</xref>), suggesting poor surgical efficacy in some patients. Previous studies have shown that patients with negative results on glycerol testing or cochlear electrograms (<xref ref-type="bibr" rid="ref8">8</xref>) and those with non-ascending audiograms (<xref ref-type="bibr" rid="ref9">9</xref>) or stage IV hearing (average hearing threshold &#x003E;70&#x2009;dB) (<xref ref-type="bibr" rid="ref3">3</xref>, <xref ref-type="bibr" rid="ref10">10</xref>) demonstrate low vertigo control rates after surgery. The characteristics of the population for which this surgery is applicable are still being explored.</p>
<p>Meniere&#x2019;s disease frequently occurs at the age of 40&#x2013;60&#x2009;years (<xref ref-type="bibr" rid="ref2">2</xref>). Compared with young healthy adults, a larger proportion of patients with MD have one or more vascular risk factors such as hyperlipidemia, hypertension, diabetes, and smoking history (<xref ref-type="bibr" rid="ref11">11</xref>, <xref ref-type="bibr" rid="ref12">12</xref>). Vascular risk factors play an important role in the development of MD. A reduction in the blood supply of the inner ear or blockage of the venous return owing to microvascular injury, oxidative stress, atherosclerotic plaque formation, and micro thrombosis affects the balance in the production and absorption of endolymphatic fluid, thereby increasing the risk of endolymphatic hydrops (<xref ref-type="bibr" rid="ref13 ref14 ref15">13&#x2013;15</xref>). Previous studies have found that patients with vascular risk factors experience vertigo attacks more frequently (<xref ref-type="bibr" rid="ref16">16</xref>) and demonstrate a poor response to routine treatment of medication (<xref ref-type="bibr" rid="ref17 ref18 ref19">17&#x2013;19</xref>). However, whether patients with vascular risk factors demonstrate poor control after ESD remains unclear. One of the difficulties of conducting research in this area may be the lack of indicators for an overall assessment of vascular risk factors.</p>
<p>Numerous vascular risk factors including hyperlipidemia, hypertension, diabetes, a smoking history, and other factors increase the risk of ischemic cardiovascular disease (<xref ref-type="bibr" rid="ref20">20</xref>); it is, therefore, inappropriate to consider only a single factor. Fortunately, the 10-year atherosclerotic cardiovascular disease (ASCVD) risk classification was recently developed to provide an overall assessment of vascular risk factors. It is recommended by the Chinese Guidelines for the Prevention of Cardiovascular Diseases (2017) (<xref ref-type="bibr" rid="ref20">20</xref>). It has been established based on results from long-term cohort studies on cardiovascular disease incidence risk in China; it is, therefore, applicable to the Chinese population and has been widely used in clinical practice. By using it for the overall evaluation of patients and comparing the differences in surgical efficacy among patients with different ASCVD risks, the effect of vascular risk factors on the efficacy of ESD could be figured out.</p>
<p>For MD patients, unpredictable and disabling vertigo episodes can disrupt normal work and life, bringing great pain (<xref ref-type="bibr" rid="ref21">21</xref>). Therefore, this study aimed to provide a reference for the ESD selection of patients with vascular risk factors in the hope of achieving a balance between function preservation and vertigo control. Individualized treatment plans could be created by the evaluation of preoperative data, and unnecessary destructive surgeries chosen due to fear of failed vertigo control could be avoided.</p>
</sec>
<sec id="sec6" sec-type="materials|methods">
<label>2.</label>
<title>Materials and methods</title>
<sec id="sec7">
<label>2.1.</label>
<title>Patients</title>
<p>This study is a retrospective cohort study. The patients who underwent unilateral ESD at the Vertigo Clinic/Research Center of Air Force Medical Center from 2013 to 2020 were included as research subjects.</p>
<p>As shown in <xref rid="fig1" ref-type="fig">Figure 1</xref>, patients conforming to the definite MD diagnosis criteria of the Clinical Practice Guideline: Meniere&#x2019;s Disease (2020) (<xref ref-type="bibr" rid="ref4">4</xref>) and with an age at operation exceeding 18&#x2009;years were included in this study. Patients with bilateral MD, those with comorbid vestibular migraine diagnosed before the operation or during follow-up (<xref ref-type="bibr" rid="ref22">22</xref>), those who had undergone other surgeries for MD (except intratympanic injection) or ESD more than once, and those who underwent follow-up for less than 2&#x2009;years or failed to attend follow-up were excluded.</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Flowchart of patient inclusion and exclusion. ESD, endolymphatic sac decompression. MD, Meniere&#x2019;s disease.</p>
</caption>
<graphic xlink:href="fneur-14-1194456-g001.tif"/>
</fig>
</sec>
<sec id="sec8">
<label>2.2.</label>
<title>Methods</title>
<sec id="sec9">
<label>2.2.1.</label>
<title>Surgical procedure and postoperative medications of ESD</title>
<p>ESD was performed based on the method reported by Shambaugh (<xref ref-type="bibr" rid="ref23">23</xref>) in 1975. A C-shaped incision was placed behind the patient&#x2019;s ear. The area of the mastoid process extending from the temporal line to the mastoid tip was then ground under the microscope. The mastoid cells were fully cleared, and the mastoid process contoured; this exposed the lateral and posterior semicircular canals and the sigmoid sinus. The endolymphatic sac was found anterior to the sigmoid sinus and between the posterior semicircular canal and the line extending from the lateral semicircular canal. An area of bone measuring 1 &#x00D7; 1&#x2009;cm<sup>2</sup> was then removed to fully expose the endolymphatic sac.</p>
<p>Data pertaining to medications used within 14&#x2009;days after ESD (including betahistine, diuretics, and hormones) were obtained.</p>
</sec>
<sec id="sec10">
<label>2.2.2.</label>
<title>The evaluation of ASCVD risk in 10&#x2009;years</title>
<p>The patients&#x2019; ASCVD risk in 10&#x2009;years was evaluated based on their smoking history, blood lipid test results, sex, age, and previous history of hypertension and diabetes (<xref ref-type="bibr" rid="ref20">20</xref>) (<xref rid="tab1" ref-type="table">Table 1</xref>). The patients with no and low risk were classified as one cohort (low-risk group), while those having medium, high, and very high risk were classified as another cohort (high-risk group). The effect of ESD was compared between the low-and high-risk groups.</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Atherosclerotic cardiovascular diseases (ASCVD) risk in a 10-year classification.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" valign="top" colspan="2" rowspan="2">The number of risk factors</th>
<th align="center" valign="top" colspan="3">Serum cholesterol (mmol/L)</th>
</tr>
<tr>
<th align="center" valign="top">3.1&#x2009;&#x2264;&#x2009;TC &#x003C;4.1 or 1.8&#x2009;&#x2264;&#x2009;LDL-C&#x2009;&#x003C;&#x2009;2.6</th>
<th align="center" valign="top">4.1&#x2009;&#x2264;&#x2009;TC &#x003C;5.2 or 2.6&#x2009;&#x2264;&#x2009;LDL-C&#x2009;&#x003C;&#x2009;3.4</th>
<th align="center" valign="top">5.2&#x2009;&#x2264;&#x2009;TC &#x003C;7.2 or 3.4&#x2009;&#x2264;&#x2009;LDL-C&#x2009;&#x003C;&#x2009;4.9</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">No hypertension</td>
<td align="center" valign="top">0&#x2009;~&#x2009;1</td>
<td align="center" valign="top">Low risk (&#x003C;5%)</td>
<td align="center" valign="top">Low risk (&#x003C;5%)</td>
<td align="center" valign="top">Low risk (&#x003C;5%)</td>
</tr>
<tr>
<td/>
<td align="center" valign="top">2</td>
<td align="center" valign="top">Low risk (&#x003C;5%)</td>
<td align="center" valign="top">Low risk (&#x003C;5%)</td>
<td align="center" valign="top">Medium risk (5%&#x2009;~&#x2009;9%)</td>
</tr>
<tr>
<td/>
<td align="center" valign="top">3</td>
<td align="center" valign="top">Low risk (&#x003C;5%)</td>
<td align="center" valign="top">Medium risk (5%&#x2009;~&#x2009;9%)</td>
<td align="center" valign="top">Medium risk (5%&#x2009;~&#x2009;9%)</td>
</tr>
<tr>
<td align="left" valign="top">Hypertension</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">Low risk (&#x003C;5%)</td>
<td align="center" valign="top">Low risk (&#x003C;5%)</td>
<td align="center" valign="top">Low risk (&#x003C;5%)</td>
</tr>
<tr>
<td/>
<td align="center" valign="top">1</td>
<td align="center" valign="top">Low risk (&#x003C;5%)</td>
<td align="center" valign="top">Medium risk (5%&#x2009;~&#x2009;9%)</td>
<td align="center" valign="top">Medium risk (5%&#x2009;~&#x2009;9%)</td>
</tr>
<tr>
<td/>
<td align="center" valign="top">2</td>
<td align="center" valign="top">Medium risk (5%&#x2009;~&#x2009;9%)</td>
<td align="center" valign="top">High risk (5%&#x2009;~&#x2009;9%)</td>
<td align="center" valign="top">High risk (5%&#x2009;~&#x2009;9%)</td>
</tr>
<tr>
<td/>
<td align="center" valign="top">3</td>
<td align="center" valign="top">High risk (5%&#x2009;~&#x2009;9%)</td>
<td align="center" valign="top">High risk (5%&#x2009;~&#x2009;9%)</td>
<td align="center" valign="top">High risk (5%&#x2009;~&#x2009;9%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>TC, total cholesterol. LDL-C, low-density lipoprotein cholesterol. HDL-C, high-density lipoprotein cholesterol. Risk factors include smoking, low HDL-C, age&#x2009;&#x2265;&#x2009;45 (men), and age&#x2009;&#x2265;&#x2009;55 (women). Patients with a history of ASCVD were directly classified as very high risk. Patients with any of the following were directly classified as high risk: history of diabetes and age&#x2009;&#x2265;&#x2009;40, LDL-C&#x2009;&#x2265;&#x2009;4.9&#x2009;mmol/L or TC&#x2009;&#x2265;&#x2009;7.2&#x2009;mmol/L, systolic pressure&#x2009;&#x2265;&#x2009;180&#x2009;mmHg or diastolic pressure&#x2009;&#x2265;&#x2009;110&#x2009;mmHg, and smoking more than 30 cigarettes a day.</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec11">
<label>2.2.3.</label>
<title>The evaluation of audiometric examination</title>
<p>Pure tone audiometry was performed on all the patients enrolled and the worst result during 6&#x2009;months before ESD was used to evaluate their hearing. The preoperative hearing threshold was defined as a pure tone average (PTA) of 0.5, 1, and 2&#x2009;kHz, and the hearing stage was classed based on it (<xref ref-type="bibr" rid="ref3">3</xref>). Audiograms were divided into ascending and non-ascending types (<xref ref-type="bibr" rid="ref24">24</xref>). The glycerol test was performed according to our previous research (<xref ref-type="bibr" rid="ref25">25</xref>).</p>
</sec>
<sec id="sec12">
<label>2.2.4.</label>
<title>Subtype classification of MD</title>
<p>The patients with non-classical MD were classified (<xref ref-type="bibr" rid="ref26">26</xref>) as having MD with migraine (<xref ref-type="bibr" rid="ref22">22</xref>), autoimmune MD, or familial MD based on their medical and family history. The remainder were classified as having classical MD.</p>
</sec>
</sec>
<sec id="sec13">
<label>2.3.</label>
<title>The evaluation of the ESD effect</title>
<sec id="sec14">
<label>2.3.1.</label>
<title>Vertigo control</title>
<p>Vertigo control was evaluated by comparing the frequency of episodes experienced before and after surgery (<xref ref-type="bibr" rid="ref27">27</xref>, <xref ref-type="bibr" rid="ref28">28</xref>). The value was calculated as follows:</p>
<p>Numerical value&#x2009;=&#x2009;(X/Y) &#x00D7; 100 (rounded to the nearest whole number), where X was the average number of definitive spells per month during 18&#x2013;24&#x2009;months after therapy, and Y was the average number of definitive spells per month during 0&#x2013;6&#x2009;months before therapy. The vertigo control class was divided into six levels based on numerical value (<xref ref-type="supplementary-material" rid="SM1">Supplementary Table S1</xref>), and the basic control rate of vertigo was defined as the proportion of patients with grade A and B vertigo control (numerical value&#x2009;&#x2264;&#x2009;40).</p>
</sec>
<sec id="sec15">
<label>2.3.2.</label>
<title>Dysfunction</title>
<p>The dysfunction score levels (one to six points) using the functional level scale (<xref ref-type="supplementary-material" rid="SM2">Supplementary Table S2</xref>) and the differences between preoperative and postoperative dysfunction were evaluated based on the functional level scale (<xref ref-type="bibr" rid="ref27">27</xref>, <xref ref-type="bibr" rid="ref28">28</xref>).</p>
</sec>
</sec>
<sec id="sec16">
<label>2.4.</label>
<title>Statistical methods</title>
<p>The SPSS 26.0 software package was used for statistical analysis. The <italic>t</italic>-test was used to compare two groups of normal data, and a non-parametric test was used to compare two groups of non-normal or grade data. The chi-square test was used to compare rates between the two groups; <italic>p</italic>&#x2009;&#x003C;&#x2009;0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="sec17" sec-type="results">
<label>3.</label>
<title>Results</title>
<sec id="sec18">
<label>3.1.</label>
<title>Basic patient characteristics</title>
<p>A total of 56 patients including 26 (46.43%) men and 30 (53.57%) women fulfilled the inclusion and exclusion criteria (<xref rid="fig1" ref-type="fig">Figure 1</xref>). The age at operation was 23&#x2013;68 (average age: 50.32&#x2009;&#x00B1;&#x2009;11.13) years and the duration of follow-up extended between 2 and 9&#x2009;years, with a median duration of 6.73 (5.57 and 7.79) years. Complete preoperative and postoperative dysfunction score data were available for 43 patients. The low-and high-risk groups demonstrated statistically significant differences in terms of sex, age at operation, and course of disease (<italic>P</italic> &#x003C;&#x2009;0.05; <xref rid="tab2" ref-type="table">Table 2</xref>). These variables were included during multivariate analysis to exclude their influence on the results. There was no statistical difference between the two groups in terms of glycerol test positivity rates, the subtype of MD, preoperative hearing threshold, hearing stage, type of audiogram, preoperative frequency of vertigo, preoperative dysfunction score, and medications used after ESD (<italic>p</italic>&#x2009;&#x003E;&#x2009;0.05).</p>
<table-wrap position="float" id="tab2">
<label>Table 2</label>
<caption>
<p>Comparison of baseline data between the low-and high-risk groups.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th/>
<th align="center" valign="top">Low-risk group (<italic>N</italic>&#x2009;=&#x2009;37)</th>
<th align="center" valign="top">High-risk group (<italic>N</italic>&#x2009;=&#x2009;19)</th>
<th align="center" valign="top">
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Sex (<italic>N</italic> [%])</td>
<td/>
<td/>
<td align="center" valign="top">0.008</td>
</tr>
<tr>
<td align="left" valign="top">Women</td>
<td align="center" valign="middle">25 (67.6%)</td>
<td align="center" valign="middle">5 (26.3%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">Men</td>
<td align="center" valign="middle">12 (32.4%)</td>
<td align="center" valign="middle">14 (73.7%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">Age/Yr (Mean&#x2009;&#x00B1;&#x2009;SD)</td>
<td align="center" valign="middle">47.59&#x2009;&#x00B1;&#x2009;11.06</td>
<td align="center" valign="middle">55.63&#x2009;&#x00B1;&#x2009;9.44</td>
<td align="center" valign="middle">0.009</td>
</tr>
<tr>
<td align="left" valign="top">Course/Yr (Median [P25, P75])</td>
<td align="center" valign="middle">2.00 (1.00,4.00)</td>
<td align="center" valign="middle">4.00 (2.50,6.50)</td>
<td align="center" valign="middle">0.024</td>
</tr>
<tr>
<td align="left" valign="top">Follow-up/Yr (Median [P25, P75])</td>
<td align="center" valign="middle">6.55 (5.47,7.48)</td>
<td align="center" valign="middle">6.94 (5.80,8.30)</td>
<td align="center" valign="middle">0.416</td>
</tr>
<tr>
<td align="left" valign="top">Subtype of MD (<italic>N</italic> [%])</td>
<td/>
<td/>
<td align="center" valign="top">1.000</td>
</tr>
<tr>
<td align="left" valign="top">Classical MD</td>
<td align="center" valign="middle">30 (81.1%)</td>
<td align="center" valign="middle">16 (84.2%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">Non-classical MD</td>
<td align="center" valign="middle">7 (18.9%)</td>
<td align="center" valign="middle">3 (15.8%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">Glycerol test (<italic>N</italic> [%])</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">Positive</td>
<td align="center" valign="middle">14 (37.8%)</td>
<td align="center" valign="middle">9 (47.4%)</td>
<td align="center" valign="middle">0.689</td>
</tr>
<tr>
<td align="left" valign="top">Negative</td>
<td align="center" valign="middle">23 (62.2%)</td>
<td align="center" valign="middle">10 (52.6%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">PTA (Mean&#x2009;&#x00B1;&#x2009;SD)</td>
<td align="center" valign="middle">50.32&#x2009;&#x00B1;&#x2009;17.62</td>
<td align="center" valign="middle">54.68&#x2009;&#x00B1;&#x2009;14.82</td>
<td align="center" valign="middle">0.360</td>
</tr>
<tr>
<td align="left" valign="top">Hearing stage (<italic>N</italic> [%])</td>
<td/>
<td/>
<td align="center" valign="middle">0.378</td>
</tr>
<tr>
<td align="left" valign="top">I</td>
<td align="center" valign="middle">4 (10.8%)</td>
<td align="center" valign="middle">1 (5.3%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">II</td>
<td align="center" valign="middle">7 (18.9%)</td>
<td align="center" valign="middle">1 (5.3%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">III</td>
<td align="center" valign="middle">23 (62.2%)</td>
<td align="center" valign="middle">16 (84.2%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">IV</td>
<td align="center" valign="middle">3 (8.1%)</td>
<td align="center" valign="middle">1 (5.3%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">Type of audiogram (<italic>N</italic> [%])</td>
<td/>
<td/>
<td align="center" valign="middle">0.794</td>
</tr>
<tr>
<td align="left" valign="top">Ascending</td>
<td align="center" valign="middle">9 (24.3%)</td>
<td align="center" valign="middle">6 (31.6%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">Non-ascending</td>
<td align="center" valign="middle">28 (75.7%)</td>
<td align="center" valign="middle">13 (68.4%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">Frequency (Median [P25, P75])</td>
<td align="center" valign="top">6.00 (2.00,12.00)</td>
<td align="center" valign="top">4.00 (1.50,10.50)</td>
<td align="center" valign="top">0.855</td>
</tr>
<tr>
<td align="left" valign="top">Dysfunction score (<italic>N</italic> [%])</td>
<td align="center" valign="top">28</td>
<td align="center" valign="top">15</td>
<td align="center" valign="middle">0.923</td>
</tr>
<tr>
<td align="left" valign="top">2</td>
<td align="center" valign="middle">9 (32.1%)</td>
<td align="center" valign="middle">4 (26.7%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">3</td>
<td align="center" valign="middle">14 (50%)</td>
<td align="center" valign="middle">8 (53.3%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">4</td>
<td align="center" valign="middle">3 (10.7%)</td>
<td align="center" valign="middle">2 (13.3%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">5</td>
<td align="center" valign="middle">1 (3.6%)</td>
<td align="center" valign="middle">1 (6.7%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">6</td>
<td align="center" valign="middle">1 (3.6%)</td>
<td align="center" valign="middle">0 (0%)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">Medication (<italic>N</italic> [%])</td>
<td align="center" valign="top">29 (85.29%)</td>
<td align="center" valign="top">17 (94.44%)</td>
<td align="center" valign="top">0.599</td>
</tr>
<tr>
<td align="left" valign="top">Betahistine</td>
<td align="center" valign="top">23 (67.65%)</td>
<td align="center" valign="top">17 (94.44%)</td>
<td align="center" valign="top">0.066</td>
</tr>
<tr>
<td align="left" valign="top">Diuretic</td>
<td align="center" valign="top">11 (32.35%)</td>
<td align="center" valign="top">6 (33.33%)</td>
<td align="center" valign="top">0.943</td>
</tr>
<tr>
<td align="left" valign="top">Hormone</td>
<td align="center" valign="top">11 (32.35%)</td>
<td align="center" valign="top">5 (27.78%)</td>
<td align="center" valign="top">0.734</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>N, number. Yr, year. SD, standard deviation. Age, age at operation. Course, Course of Meniere&#x2019;s disease. MD, Meniere&#x2019;s disease. PTA, pure tone average of 0.5, 1, and 2&#x2009;kHz. Frequency: the number of monthly vertigo attacks during the 6&#x2009;months before the operation. Medication: the use of betahistine, diuretic, or hormone after the operation.</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec19">
<label>3.2.</label>
<title>Comparison of the effect of ESD between low-and high-risk groups</title>
<p>The basic control rates of vertigo in the low-and high-risk groups were 78.95 and 81.08%, respectively (<xref rid="tab3" ref-type="table">Table 3</xref>); no statistical differences were observed between the vertigo control classes of the two groups (<italic>Z</italic>&#x2009;=&#x2009;&#x2013;0.07, <italic>p</italic>&#x2009;=&#x2009;0.96). The risk of failing to achieve basic control of vertigo did not significantly increase in the high-risk group (relative risk&#x2009;=&#x2009;0.90, 95% confidence interval: 0.30&#x2013;2.69, <italic>p</italic>&#x2009;=&#x2009;1.00).</p>
<table-wrap position="float" id="tab3">
<label>Table 3</label>
<caption>
<p>Comparison of postoperative vertigo control classes between low-and high-risk groups.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Vertigo control class</th>
<th align="center" valign="top">Low-risk group (<italic>N</italic> [%]) (<italic>N</italic>&#x2009;=&#x2009;37)</th>
<th align="center" valign="top">High-risk group (<italic>N</italic> [%]) (<italic>N</italic>&#x2009;=&#x2009;19)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">A</td>
<td align="center" valign="middle">22 (59.5%)</td>
<td align="center" valign="middle">12 (63.2%)</td>
</tr>
<tr>
<td align="left" valign="top">B</td>
<td align="center" valign="middle">8 (21.6%)</td>
<td align="center" valign="middle">3 (15.8%)</td>
</tr>
<tr>
<td align="left" valign="top">C</td>
<td align="center" valign="middle">1 (2.7%)</td>
<td align="center" valign="middle">0 (0.0%)</td>
</tr>
<tr>
<td align="left" valign="top">D</td>
<td align="center" valign="middle">1 (2.7%)</td>
<td align="center" valign="middle">0 (0.0%)</td>
</tr>
<tr>
<td align="left" valign="top">E</td>
<td align="center" valign="middle">0 (0.0%)</td>
<td align="center" valign="middle">0 (0.0%)</td>
</tr>
<tr>
<td align="left" valign="top">F</td>
<td align="center" valign="middle">5 (13.5%)</td>
<td align="center" valign="middle">4 (21.1%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>N, number of patients.</p>
</table-wrap-foot>
</table-wrap>
<p>Compared with the scores before surgery, the postoperative dysfunction scores decreased significantly among patients from both groups (low-risk group: <italic>Z</italic>&#x2009;=&#x2009;&#x2013;4.51, <italic>p</italic>&#x2009;&#x003C;&#x2009;0.01; high-risk group: <italic>Z</italic>&#x2009;=&#x2009;&#x2013;3.11, <italic>p</italic>&#x2009;&#x003C;&#x2009;0.01); both groups demonstrated a median decrease of two (<xref ref-type="bibr" rid="ref1">1</xref>, <xref ref-type="bibr" rid="ref2">2</xref>) points and the difference was not statistically significant (<italic>Z</italic>&#x2009;=&#x2009;&#x2013;0.46, <italic>p</italic>&#x2009;=&#x2009;0.65).</p>
</sec>
<sec id="sec20">
<label>3.3.</label>
<title>Multivariate binary logistic regression analysis</title>
<p>Considering the failure of basic vertigo control as a positive event, the multivariate binary logistic regression equation was constructed using the following variables: risk of ASCVD in 10&#x2009;years, sex, age at operation, and course of the disease. The Hosmer-Lemeshow test showed a good model fit (<italic>p</italic>&#x2009;=&#x2009;0.51). After adjusting for sex, age at operation, and course of the disease, the results showed that inclusion in the high-risk group had no statistically significant impact on the failure of basic vertigo control (<italic>p</italic>&#x2009;=&#x2009;0.13; <xref rid="tab4" ref-type="table">Table 4</xref>).</p>
<table-wrap position="float" id="tab4">
<label>Table 4</label>
<caption>
<p>Multivariate binary logistic regression model for basic vertigo control.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Variables</th>
<th/>
<th align="center" valign="top">
<italic>b</italic>
</th>
<th align="center" valign="top">SE of <italic>b</italic></th>
<th align="center" valign="top">
<italic>X<sup>2</sup></italic>
</th>
<th align="center" valign="top">
<italic>P</italic>
</th>
<th align="center" valign="top">OR (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Sex</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td/>
<td align="left" valign="top">Women</td>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td/>
<td align="left" valign="top">Men</td>
<td align="center" valign="top">1.66</td>
<td align="center" valign="top">0.97</td>
<td align="center" valign="top">2.93</td>
<td align="center" valign="top">0.09</td>
<td align="center" valign="top">5.27 (0.79, 35.33)</td>
</tr>
<tr>
<td align="left" valign="top">Age at operation/Yr</td>
<td/>
<td align="center" valign="top">0.10</td>
<td align="center" valign="top">0.05</td>
<td align="center" valign="top">5.26</td>
<td align="center" valign="top">0.02</td>
<td align="center" valign="top">1.11 (1.02, 1.21)</td>
</tr>
<tr>
<td align="left" valign="top">The course of disease/Yr</td>
<td/>
<td align="center" valign="top">0.05</td>
<td align="center" valign="top">0.04</td>
<td align="center" valign="top">1.61</td>
<td align="center" valign="top">0.20</td>
<td align="center" valign="top">1.05 (0.97, 1.14)</td>
</tr>
<tr>
<td align="left" valign="top">Risk of ASCVD in 10&#x2009;years</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td/>
<td align="left" valign="top">Low risk</td>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td/>
<td align="left" valign="top">High risk</td>
<td align="center" valign="top">&#x2212;1.62</td>
<td align="center" valign="top">1.08</td>
<td align="center" valign="top">2.24</td>
<td align="center" valign="top">0.13</td>
<td align="center" valign="top">0.20 (0.02, 1.65)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>SE, standard error. OR, odds ratio. CI, confidence interval.</p>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="sec21" sec-type="discussions">
<label>4.</label>
<title>Discussion</title>
<p>In this retrospective cohort study, the results of statistical analyses showed that the basic vertigo control rate was nearly 80% in both low-and high-risk groups. There was no statistical difference between the two groups regardless of whether variables such as sex, age at operation, and course of disease were controlled. In addition, the postoperative dysfunction score decreased significantly in both groups. This suggested that the existence of vascular risk factors did not worsen surgical efficacy in these patients. The patients experienced good vertigo control and the disease-related dysfunction had been resolved.</p>
<p>Since the introduction of ESD in 1927, surgical outcomes have varied across different studies (<xref ref-type="bibr" rid="ref5 ref6 ref7">5&#x2013;7</xref>). As this may be attributed to differences in the included patient groups, it is essential to identify the clinical characteristics of patients who are appropriate candidates for this operation; this may help predict the surgical benefit and reduce unnecessary surgical intervention (<xref ref-type="bibr" rid="ref29">29</xref>). The age associated with a high incidence of MD partly overlaps with that associated with a high incidence of vascular risk factors (such as hypertension, hyperlipidemia, and diabetes). In this context, patients with vascular risk factors have more severe symptoms and a poorer prognosis. As vascular risk factors may affect surgical efficacy, this study compared the surgical efficacy between low-and high-risk patients and found vascular risk factors to have no significant effect.</p>
<p>This finding, which was inconsistent with our expectations, demonstrated the complexity of the mechanisms involved in the etiopathogenesis of MD. Findings from existing studies suggest that patients with a greater number of vascular risk factors obtain less benefit from routine treatment; however, the patients in this study experienced good outcomes after ESD. This may be attributed to the fact that the operation alleviates the rapid expansion of membranous labyrinthine hydrops rather than cures it. Notably, the membranous labyrinthine hydrops caused by vascular risk factors or other causes persists after surgery (<xref ref-type="bibr" rid="ref30">30</xref>). The operation just prevents further aggravation of the condition owing to arteriovenous mixing, which may result from endolymphatic sac vessel reflux to the inner ear due to excessive pressure (<xref ref-type="bibr" rid="ref31">31</xref>). Current research suggests that vertigo attacks are related to the rupture of the membranous labyrinth which is caused by an acute increase in endolymph rather than hydrops itself (<xref ref-type="bibr" rid="ref32">32</xref>), which happened in 12.5&#x2013;30.0% of healthy individuals (<xref ref-type="bibr" rid="ref33">33</xref>). The operation provides space for the expansion of the endolymph sac; this in turn prevents any serious organ damage caused by rapid hydrops and thereby achieves the goal of reducing vertigo attacks. Patients with one or more vascular risk factors may therefore still obtain good control of vertigo despite the existence of membranous labyrinthine hydrops.</p>
<p>The greatest strength of our study is the control of confounding bias. As numerous factors may influence the efficacy of ESD, it is difficult to identify the actual impact of vascular risk factors. Therefore, the baseline data from the low-and high-risk groups were compared to control interference from heterogeneity in demographic characteristics (sex, age, and time of follow-up), etiology (a subtype of MD), state of hydrops (results of the glycerol test), progress and severity of MD (course of disease, hearing stage, type of audiogram, preoperative hearing threshold, preoperative frequency of vertigo, and preoperative dysfunction score), and medications used after ESD. For variables that demonstrated an imbalance in distribution between the groups (such as sex, age, and course of the disease), multifactorial analysis was performed to control their influence. Compared with single factor analysis, which does not consider the impact of other factors on ESD, our analysis fully considered various factors that affect postoperative vertigo control (<xref ref-type="bibr" rid="ref8 ref9 ref10">8&#x2013;10</xref>, <xref ref-type="bibr" rid="ref34">34</xref>) and identified the exclusive impact of vascular risk factors with considerable reliability.</p>
<p>Our study had certain limitations. First, the sample size was relatively small; the findings, therefore, need to be validated in large-scale and multi-center studies. Second, the impact of vasopressin on the ESD effect was not controlled because of the lack of prospective design. Vasopressin was proved to correlate with MD attack by overexpressing vasopressin type-2 receptor and subsequently activating aquaporin-2 (<xref ref-type="bibr" rid="ref35">35</xref>, <xref ref-type="bibr" rid="ref36">36</xref>), which may interfere with the evaluation of ESD efficacy. Third, on ASCVD risk stratification, only one patient in this study demonstrated no risk in 10&#x2009;years; the sample size for comparison and analysis of surgical effects in patients with/without vascular risk factors was therefore limited. Fourth, the control of vascular risk factors during follow-up was not assessed in this study, which limited further demonstration of the vascular risk factors&#x2019; impact on ESD efficacy. A prospective study is needed to confirm if the changes in vascular risk factors can lead to changes in ESD efficacy. Last but not least, ASCVD risk in 10&#x2009;years may not be an optimal indicator for a comprehensive evaluation of vascular risk factors. It focuses on the occurrence of ASCVD, in which the vascular lesions are more severe than those of MD. Further research will therefore be performed using more appropriate indicators.</p>
<p>Finally, it is worth noting that maintaining a healthy lifestyle and control of vascular risk factors are still necessary for MD patients because of the high disability rate and mortality of cerebral or myocardial infarction even though the finding above suggests that ESD efficacy is not much affected by vascular risk factors.</p>
</sec>
<sec id="sec22" sec-type="conclusions">
<label>5.</label>
<title>Conclusion</title>
<p>In conclusion, ESD may effectively reduce vertigo attacks and dysfunction in patients with MD, and its efficacy is not reduced by an increase in vascular risk factors. The findings from this study may increase confidence regarding the use of ESD in patients with MD, thereby preventing unnecessary destructive surgeries.</p>
</sec>
<sec id="sec23" sec-type="data-availability">
<title>Data availability statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="sec24">
<title>Ethics statement</title>
<p>The studies involving human participants were reviewed and approved by Medical Ethics Committee of Air Force Medical Center. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.</p>
</sec>
<sec id="sec25">
<title>Author contributions</title>
<p>ZJ and CW designed the research. FG, YG, and YL prepared the material, collected the data, and analyzed the data. YL prepared the figures. XX and YL wrote the first draft of the manuscript. All authors contributed to the study&#x2019;s conception and design, commented on previous versions of the manuscript, and read and approved the final manuscript.</p>
</sec>
<sec id="sec26" sec-type="funding-information">
<title>Funding</title>
<p>This study has been funded by the major program of the PLA logistics department (number: BKJ19J020).</p>
</sec>
<sec id="conf1" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="sec100" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<ack>
<p>We would like to thank all participants for their time during this study.</p>
</ack>
<sec id="sec28" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fneur.2023.1194456/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fneur.2023.1194456/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Table_1.docx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table_2.docx" id="SM2" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1">
<label>1.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakashima</surname> <given-names>T</given-names></name> <name><surname>Pyykk&#x00F6;</surname> <given-names>I</given-names></name> <name><surname>Arroll</surname> <given-names>MA</given-names></name> <name><surname>Casselbrant</surname> <given-names>ML</given-names></name> <name><surname>Foster</surname> <given-names>CA</given-names></name> <name><surname>Manzoor</surname> <given-names>NF</given-names></name> <etal/></person-group>. <article-title>Meniere's disease</article-title>. <source>Nat Rev Dis Primers</source>. (<year>2016</year>) <volume>2</volume>:<fpage>16028</fpage>. doi: <pub-id pub-id-type="doi">10.1038/nrdp.2016.28</pub-id></citation>
</ref>
<ref id="ref2">
<label>2.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sajjadi</surname> <given-names>H</given-names></name> <name><surname>Paparella</surname> <given-names>MM</given-names></name></person-group>. <article-title>Meniere's disease</article-title>. <source>Lancet</source>. (<year>2008</year>) <volume>372</volume>:<fpage>406</fpage>&#x2013;<lpage>14</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(08)61161-7</pub-id></citation>
</ref>
<ref id="ref3">
<label>3.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname> <given-names>X</given-names></name> <name><surname>Kong</surname> <given-names>W</given-names></name> <name><surname>Leng</surname> <given-names>Y</given-names></name> <name><surname>Liu</surname> <given-names>B</given-names></name> <name><surname>Lin</surname> <given-names>B</given-names></name> <name><surname>Yu</surname> <given-names>L</given-names></name> <etal/></person-group>. <article-title>Guideline of diagnosis and treatment of meniere disease (2017)</article-title>. <source>Chin J Otorhinolaryngol Head Neck Surg</source>. (<year>2017</year>) <volume>52</volume>:<fpage>167</fpage>&#x2013;<lpage>72</lpage>. <comment>Chinese</comment>. doi: <pub-id pub-id-type="doi">10.3760/cma.j.issn.1673-0860.2017.03.002</pub-id></citation>
</ref>
<ref id="ref4">
<label>4.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Basura</surname> <given-names>GJ</given-names></name> <name><surname>Adams</surname> <given-names>ME</given-names></name> <name><surname>Monfared</surname> <given-names>A</given-names></name> <name><surname>Schwartz</surname> <given-names>SR</given-names></name> <name><surname>Antonelli</surname> <given-names>PJ</given-names></name> <name><surname>Burkard</surname> <given-names>R</given-names></name> <etal/></person-group>. <article-title>Clinical practice guideline: M&#x00E9;ni&#x00E8;re's disease executive summary</article-title>. <source>Otolaryngol Head Neck Surg</source>. (<year>2020</year>) <volume>162</volume>:<fpage>415</fpage>&#x2013;<lpage>34</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0194599820909439</pub-id>, PMID: <pub-id pub-id-type="pmid">32267820</pub-id></citation>
</ref>
<ref id="ref5">
<label>5.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Flores</surname> <given-names>GM</given-names></name> <name><surname>Llata</surname> <given-names>SC</given-names></name> <name><surname>Cisneros</surname> <given-names>LJ</given-names></name> <name><surname>Pane</surname> <given-names>PC</given-names></name></person-group>. <article-title>Endolymphatic sac surgery for m&#x00E9;ni&#x00E8;re's disease - current opinion and literature review</article-title>. <source>Int Arch Otorhinolaryngol</source>. (<year>2017</year>) <volume>21</volume>:<fpage>179</fpage>&#x2013;<lpage>83</lpage>. doi: <pub-id pub-id-type="doi">10.1055/s-0037-1599276</pub-id>, PMID: <pub-id pub-id-type="pmid">28382128</pub-id></citation>
</ref>
<ref id="ref6">
<label>6.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brinson</surname> <given-names>GM</given-names></name> <name><surname>Chen</surname> <given-names>DA</given-names></name> <name><surname>Arriaga</surname> <given-names>MA</given-names></name></person-group>. <article-title>Endolymphatic mastoid shunt versus endolymphatic sac decompression for M&#x00E9;ni&#x00E8;re's disease</article-title>. <source>Otolaryngol Head Neck Surg</source>. (<year>2007</year>) <volume>136</volume>:<fpage>415</fpage>&#x2013;<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.otohns.2006.08.031</pub-id>, PMID: <pub-id pub-id-type="pmid">17321870</pub-id></citation>
</ref>
<ref id="ref7">
<label>7.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sennaroglu</surname> <given-names>L</given-names></name> <name><surname>Sennaroglu</surname> <given-names>G</given-names></name> <name><surname>Gursel</surname> <given-names>B</given-names></name> <name><surname>Dini</surname> <given-names>FM</given-names></name></person-group>. <article-title>Intratympanic dexamethasone, intratympanic gentamicin, and endolymphatic sac surgery for intractable vertigo in Meniere's disease</article-title>. <source>Otolaryngol Head Neck Surg</source>. (<year>2001</year>) <volume>125</volume>:<fpage>537</fpage>&#x2013;<lpage>43</lpage>. doi: <pub-id pub-id-type="doi">10.1067/mhn.2001.119485</pub-id>, PMID: <pub-id pub-id-type="pmid">11700457</pub-id></citation>
</ref>
<ref id="ref8">
<label>8.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>YP</given-names></name> <name><surname>Yang</surname> <given-names>J</given-names></name> <name><surname>Zhou</surname> <given-names>X</given-names></name></person-group>. <article-title>The prognostic value of glycerol test of electrocochleography on the effects of endolymphatic sac decompression surgery in patients with unilateral Meniere's disease</article-title>. <source>Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</source>. (<year>2019</year>). <comment>Chinese</comment>) <volume>33</volume>:<fpage>485</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.13201/j.issn.1001-1781.2019.06.002</pub-id>, PMID: <pub-id pub-id-type="pmid">31163517</pub-id></citation>
</ref>
<ref id="ref9">
<label>9.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Han</surname> <given-names>L</given-names></name> <name><surname>Li-Sheng</surname> <given-names>YU</given-names></name> <name><surname>Liu</surname> <given-names>Y</given-names></name> <name><surname>Xia</surname> <given-names>YM</given-names></name> <name><surname>Otolaryngology</surname> <given-names>DO</given-names></name></person-group>. <article-title>Factors affecting quality of life after endolymphatic sac surgery</article-title>. <source>Chin J Otol</source>. (<year>2013</year>) <volume>11</volume>:<fpage>423</fpage>&#x2013;<lpage>7</lpage>. <comment>Chinese</comment>. doi: <pub-id pub-id-type="doi">10.3969/j.issn.1672-2922.2013.03.019</pub-id></citation>
</ref>
<ref id="ref10">
<label>10.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>H</given-names></name> <name><surname>Fengzhi</surname> <given-names>SI</given-names></name> <name><surname>Lisheng</surname> <given-names>YU</given-names></name> <name><surname>Ruiming</surname> <given-names>X</given-names></name> <name><surname>Hongwei</surname> <given-names>Z</given-names></name> <name><surname>Yuanyuan</surname> <given-names>J</given-names></name> <etal/></person-group>. <article-title>Efficacy comparison between endolymphatic sac surgery and semicircular canal occlusion in the treatment of stage 4 M&#x00E9;ni&#x00E8;re disease</article-title>. <source>J Clin Otorhinolaryngol Head Neck Surg</source>. (<year>2016</year>) <volume>30</volume>:<fpage>12</fpage>&#x2013;<lpage>4</lpage>. <comment>Chinese</comment>. doi: <pub-id pub-id-type="doi">10.13201/j.issn.1001-1781.2016.01.004</pub-id></citation>
</ref>
<ref id="ref11">
<label>11.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname> <given-names>CA</given-names></name>
</person-group>. <article-title>Optimal management of M&#x00E9;ni&#x00E8;re's disease</article-title>. <source>Ther Clin Risk Manag</source>. (<year>2015</year>) <volume>11</volume>:<fpage>301</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.2147/TCRM.S59023</pub-id>, PMID: <pub-id pub-id-type="pmid">25750534</pub-id></citation>
</ref>
<ref id="ref12">
<label>12.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>SY</given-names></name> <name><surname>Chung</surname> <given-names>J</given-names></name> <name><surname>Yoo</surname> <given-names>DM</given-names></name> <name><surname>Kwon</surname> <given-names>MJ</given-names></name> <name><surname>Kim</surname> <given-names>JH</given-names></name> <name><surname>Kim</surname> <given-names>JH</given-names></name> <etal/></person-group>. <article-title>Smoking is positively related and alcohol consumption is negatively related to an increased risk of Meniere's disease</article-title>. <source>J Clin Med</source>. (<year>2022</year>) <volume>11</volume>:<fpage>5007</fpage>. doi: <pub-id pub-id-type="doi">10.3390/jcm11175007</pub-id>, PMID: <pub-id pub-id-type="pmid">36078935</pub-id></citation>
</ref>
<ref id="ref13">
<label>13.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horton</surname> <given-names>WB</given-names></name> <name><surname>Barrett</surname> <given-names>EJ</given-names></name></person-group>. <article-title>Microvascular dysfunction in diabetes mellitus and cardiometabolic disease</article-title>. <source>Endocr Rev</source>. (<year>2021</year>) <volume>42</volume>:<fpage>29</fpage>&#x2013;<lpage>55</lpage>. doi: <pub-id pub-id-type="doi">10.1210/endrev/bnaa025</pub-id>, PMID: <pub-id pub-id-type="pmid">33125468</pub-id></citation>
</ref>
<ref id="ref14">
<label>14.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wada</surname> <given-names>M</given-names></name> <name><surname>Takeshima</surname> <given-names>T</given-names></name> <name><surname>Nakamura</surname> <given-names>Y</given-names></name> <name><surname>Nagasaka</surname> <given-names>S</given-names></name> <name><surname>Kamesaki</surname> <given-names>T</given-names></name> <name><surname>Kajii</surname> <given-names>E</given-names></name></person-group>. <article-title>Carotid plaque is a new risk factor for peripheral vestibular disorder: a retrospective cohort study</article-title>. <source>Medicine (Baltimore)</source>. (<year>2016</year>) <volume>95</volume>:<fpage>e4510</fpage>. doi: <pub-id pub-id-type="doi">10.1097/MD.0000000000004510</pub-id>, PMID: <pub-id pub-id-type="pmid">27495105</pub-id></citation>
</ref>
<ref id="ref15">
<label>15.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friis</surname> <given-names>M</given-names></name> <name><surname>S&#x00F8;rensen</surname> <given-names>MS</given-names></name> <name><surname>Qvortrup</surname> <given-names>K</given-names></name></person-group>. <article-title>The vein of the vestibular aqueduct with potential pathologic perspectives</article-title>. <source>Otol Neurotol</source>. (<year>2008</year>) <volume>29</volume>:<fpage>73</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1097/mao.0b013e31815c4d68</pub-id>, PMID: <pub-id pub-id-type="pmid">18199960</pub-id></citation>
</ref>
<ref id="ref16">
<label>16.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rego</surname> <given-names>&#x00C2;R</given-names></name> <name><surname>Dias</surname> <given-names>D</given-names></name> <name><surname>Pinto</surname> <given-names>A</given-names></name> <name><surname>Castro</surname> <given-names>SSE</given-names></name> <name><surname>Feliciano</surname> <given-names>T</given-names></name> <name><surname>Sousa</surname> <given-names>CAE</given-names></name></person-group>. <article-title>The cardiovascular aspects of a M&#x00E9;ni&#x00E8;re's disease population &#x2013; a pilot study</article-title>. <source>J Otol</source>. (<year>2019</year>) <volume>14</volume>:<fpage>51</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.joto.2019.01.004</pub-id>, PMID: <pub-id pub-id-type="pmid">31223301</pub-id></citation>
</ref>
<ref id="ref17">
<label>17.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>CY</given-names></name> <name><surname>Young</surname> <given-names>YH</given-names></name></person-group>. <article-title>Effect of smoking on the treatment of vertigo</article-title>. <source>Otol Neurotol</source>. (<year>2001</year>) <volume>22</volume>:<fpage>369</fpage>&#x2013;<lpage>72</lpage>. doi: <pub-id pub-id-type="doi">10.1097/00129492-200105000-00016</pub-id>, PMID: <pub-id pub-id-type="pmid">11347641</pub-id></citation>
</ref>
<ref id="ref18">
<label>18.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moln&#x00E1;r</surname> <given-names>A</given-names></name> <name><surname>Stefani</surname> <given-names>M</given-names></name> <name><surname>Tam&#x00E1;s</surname> <given-names>L</given-names></name> <name><surname>Szirmai</surname> <given-names>&#x00C1;</given-names></name></person-group>. <article-title>Possible effect of diabetes and hypertension on the quality of life of patients suffering from M&#x00E9;ni&#x00E8;re's disease</article-title>. <source>Orv Hetil</source>. (<year>2019</year>) <volume>160</volume>:<fpage>144</fpage>&#x2013;<lpage>50</lpage>. doi: <pub-id pub-id-type="doi">10.1556/650.2019.31256</pub-id>, PMID: <pub-id pub-id-type="pmid">30661384</pub-id></citation>
</ref>
<ref id="ref19">
<label>19.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piesk&#x00E4;</surname> <given-names>T</given-names></name> <name><surname>Kotim&#x00E4;ki</surname> <given-names>J</given-names></name> <name><surname>M&#x00E4;nnikk&#x00F6;</surname> <given-names>M</given-names></name> <name><surname>Sorri</surname> <given-names>M</given-names></name> <name><surname>Hietikko</surname> <given-names>E</given-names></name></person-group>. <article-title>Concomitant diseases and their effect on disease prognosis in Meniere's disease: diabetes mellitus identified as a negative prognostic factor</article-title>. <source>Acta Otolaryngol</source>. (<year>2018</year>) <volume>138</volume>:<fpage>36</fpage>&#x2013;<lpage>40</lpage>. doi: <pub-id pub-id-type="doi">10.1080/00016489.2017.1373850</pub-id>, PMID: <pub-id pub-id-type="pmid">28914106</pub-id></citation>
</ref>
<ref id="ref20">
<label>20.</label>
<citation citation-type="journal"><person-group person-group-type="author">
<collab id="coll1">Writing Group of Chinese Guidelines for Cardiovascular Disease Prevention; Editorial Committee of the Chinese Journal of Cardiovascular Diseases</collab>
</person-group>. <article-title>Chinese guidelines for the prevention of cardiovascular diseases (2017)</article-title>. <source>Zhonghua Xin Xue Guan Bing Za Zhi</source>. (<year>2018</year>) <volume>46</volume>:<fpage>10</fpage>&#x2013;<lpage>25</lpage>. doi: <pub-id pub-id-type="doi">10.3760/cma.j.issn.0253-3758.2018.01.004</pub-id></citation>
</ref>
<ref id="ref21">
<label>21.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>A</given-names></name> <name><surname>Webster</surname> <given-names>KE</given-names></name> <name><surname>George</surname> <given-names>B</given-names></name> <name><surname>Harrington-Benton</surname> <given-names>NA</given-names></name> <name><surname>Judd</surname> <given-names>O</given-names></name> <name><surname>Kaski</surname> <given-names>D</given-names></name> <etal/></person-group>. <article-title>Surgical interventions for M&#x00E9;ni&#x00E8;re's disease</article-title>. <source>Cochrane Database Syst Rev</source>. (<year>2023</year>) <volume>2</volume>:<fpage>CD015249</fpage>. doi: <pub-id pub-id-type="doi">10.1002/14651858.CD015249.pub2</pub-id>, PMID: <pub-id pub-id-type="pmid">36825750</pub-id></citation>
</ref>
<ref id="ref22">
<label>22.</label>
<citation citation-type="journal"><person-group person-group-type="author">
<collab id="coll2">Headache Classification Committee of the International Headache Society (IHS)</collab>
</person-group>. <article-title>The international classification of headache disorders, 3rd edition</article-title>. <source>Cephalalgia</source>. (<year>2018</year>) <volume>38</volume>:<fpage>1</fpage>&#x2013;<lpage>211</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0333102417738202</pub-id></citation>
</ref>
<ref id="ref23">
<label>23.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shambaugh</surname> <given-names>GJ</given-names></name>
</person-group>. <article-title>Effect of endolymphatic sac decompression on fluctuant hearing loss</article-title>. <source>Otolaryngol Clin N Am</source>. (<year>1975</year>) <volume>8</volume>:<fpage>537</fpage>&#x2013;<lpage>40</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0030-6665(20)32810-3</pub-id>, PMID: <pub-id pub-id-type="pmid">1153216</pub-id></citation>
</ref>
<ref id="ref24">
<label>24.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hannula</surname> <given-names>S</given-names></name> <name><surname>Bloigu</surname> <given-names>R</given-names></name> <name><surname>Majamaa</surname> <given-names>K</given-names></name> <name><surname>Sorri</surname> <given-names>M</given-names></name> <name><surname>M&#x00E4;ki-Torkko</surname> <given-names>E</given-names></name></person-group>. <article-title>Audiogram configurations among older adults: prevalence and relation to self-reported hearing problems</article-title>. <source>Int J Audiol</source>. (<year>2011</year>) <volume>50</volume>:<fpage>793</fpage>&#x2013;<lpage>801</lpage>. doi: <pub-id pub-id-type="doi">10.3109/14992027.2011.593562</pub-id>, PMID: <pub-id pub-id-type="pmid">21916791</pub-id></citation>
</ref>
<ref id="ref25">
<label>25.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>M</given-names></name> <name><surname>Jin</surname> <given-names>Z</given-names></name> <name><surname>Xu</surname> <given-names>X</given-names></name> <name><surname>Zhang</surname> <given-names>Y</given-names></name> <name><surname>Li</surname> <given-names>Y</given-names></name> <name><surname>Luo</surname> <given-names>J</given-names></name></person-group>. <article-title>Diagnostic values of intravenous glycerol test and inner ear imaging with intratympanic gadolinium injection in Meniere's disease</article-title>. <source>Chin J Otol</source>. (<year>2016</year>) <volume>14</volume>:<fpage>499</fpage>&#x2013;<lpage>503</lpage>. doi: <pub-id pub-id-type="doi">10.3969/j.issn.1672-2922.2016.04.014</pub-id></citation>
</ref>
<ref id="ref26">
<label>26.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoskin</surname> <given-names>JL</given-names></name>
</person-group>. <article-title>M&#x00E9;ni&#x00E8;re's disease: new guidelines, subtypes, imaging, and more</article-title>. <source>Curr Opin Neurol</source>. (<year>2022</year>) <volume>35</volume>:<fpage>90</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1097/WCO.0000000000001021</pub-id>, PMID: <pub-id pub-id-type="pmid">34864755</pub-id></citation>
</ref>
<ref id="ref27">
<label>27.</label>
<citation citation-type="journal"><person-group person-group-type="author">
<collab id="coll3">American academy of otolaryngology-head and neck foundation</collab>
</person-group>. <article-title>Committee on hearing and equilibrium guidelines for the diagnosis and evaluation of therapy in meni&#x00E8;re's disease</article-title>. <source>Otolaryngol Head Neck Surg</source>. (<year>1995</year>) <volume>113</volume>:<fpage>181</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0194-5998(95)70102-8</pub-id>, PMID: <pub-id pub-id-type="pmid">7675476</pub-id></citation>
</ref>
<ref id="ref28">
<label>28.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Basura</surname> <given-names>GJ</given-names></name> <name><surname>Adams</surname> <given-names>ME</given-names></name> <name><surname>Monfared</surname> <given-names>A</given-names></name> <name><surname>Schwartz</surname> <given-names>SR</given-names></name> <name><surname>Antonelli</surname> <given-names>PJ</given-names></name> <name><surname>Burkard</surname> <given-names>R</given-names></name> <etal/></person-group>. <article-title>Clinical practice guideline: M&#x00E9;ni&#x00E8;re's disease</article-title>. <source>Otolaryngol Head Neck Surg</source>. (<year>2020</year>) <volume>162</volume>:<fpage>S1</fpage>&#x2013;<lpage>S55</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0194599820909438</pub-id>, PMID: <pub-id pub-id-type="pmid">32267799</pub-id></citation>
</ref>
<ref id="ref29">
<label>29.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kinney</surname> <given-names>SE</given-names></name>
</person-group>. <article-title>Patient selection criteria for endolymphatic sac surgery, vestibular neurectomy, and labyrinthectomy</article-title>. <source>Otolaryngol Clin N Am</source>. (<year>1980</year>) <volume>13</volume>:<fpage>731</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0030-6665(20)32331-8</pub-id>, PMID: <pub-id pub-id-type="pmid">7454333</pub-id></citation>
</ref>
<ref id="ref30">
<label>30.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname> <given-names>A</given-names></name> <name><surname>Hu</surname> <given-names>J</given-names></name> <name><surname>Wang</surname> <given-names>Q</given-names></name> <name><surname>Pan</surname> <given-names>X</given-names></name> <name><surname>Zhang</surname> <given-names>Z</given-names></name> <name><surname>Jiang</surname> <given-names>W</given-names></name> <etal/></person-group>. <article-title>A comparison of endolymphatic duct blockage, endolymphatic sac drainage and endolymphatic sac decompression surgery in reversing endolymphatic hydrops in Meniere's disease</article-title>. <source>J Otolaryngol Head Neck Surg</source>. (<year>2021</year>) <volume>50</volume>:<fpage>70</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40463-021-00545-7</pub-id>, PMID: <pub-id pub-id-type="pmid">34930474</pub-id></citation>
</ref>
<ref id="ref31">
<label>31.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Attanasio</surname> <given-names>G</given-names></name> <name><surname>Califano</surname> <given-names>L</given-names></name> <name><surname>Bruno</surname> <given-names>A</given-names></name> <name><surname>Giugliano</surname> <given-names>V</given-names></name> <name><surname>Ralli</surname> <given-names>M</given-names></name> <name><surname>Martellucci</surname> <given-names>S</given-names></name> <etal/></person-group>. <article-title>Chronic cerebrospinal venous insufficiency and meni&#x00E8;re's disease: interventional versus medical therapy</article-title>. <source>Laryngoscope</source>. (<year>2020</year>) <volume>130</volume>:<fpage>2040</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1002/lary.28389</pub-id>, PMID: <pub-id pub-id-type="pmid">31710712</pub-id></citation>
</ref>
<ref id="ref32">
<label>32.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname> <given-names>T</given-names></name> <name><surname>Takeda</surname> <given-names>S</given-names></name> <name><surname>Kakigi</surname> <given-names>A</given-names></name></person-group>. <article-title>A possible mechanism of the formation of endolymphatic hydrops and its associated inner ear disorders</article-title>. <source>Auris Nasus Larynx</source>. (<year>2020</year>) <volume>47</volume>:<fpage>25</fpage>&#x2013;<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.anl.2019.09.005</pub-id>, PMID: <pub-id pub-id-type="pmid">31623941</pub-id></citation>
</ref>
<ref id="ref33">
<label>33.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>van der Lubbe</surname> <given-names>M</given-names></name> <name><surname>Vaidyanathan</surname> <given-names>A</given-names></name> <name><surname>Van Rompaey</surname> <given-names>V</given-names></name> <name><surname>Postma</surname> <given-names>AA</given-names></name> <name><surname>Bruintjes</surname> <given-names>TD</given-names></name> <name><surname>Kimenai</surname> <given-names>DM</given-names></name> <etal/></person-group>. <article-title>The "hype" of hydrops in classifying vestibular disorders: a narrative review</article-title>. <source>J Neurol</source>. (<year>2020</year>) <volume>267</volume>:<fpage>197</fpage>&#x2013;<lpage>211</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00415-020-10278-8</pub-id>, PMID: <pub-id pub-id-type="pmid">33201310</pub-id></citation>
</ref>
<ref id="ref34">
<label>34.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Teufert</surname> <given-names>KB</given-names></name> <name><surname>Berliner</surname> <given-names>KI</given-names></name> <name><surname>De la Cruz</surname> <given-names>T</given-names></name></person-group>. <article-title>Persistent dizziness after surgical treatment of vertigo: an exploratory study of prognostic factors</article-title>. <source>Otol Neurotol</source>. (<year>2007</year>) <volume>28</volume>:<fpage>1056</fpage>&#x2013;<lpage>62</lpage>. doi: <pub-id pub-id-type="doi">10.1097/MAO.0b013e318157fdd0</pub-id></citation>
</ref>
<ref id="ref35">
<label>35.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kitahara</surname> <given-names>T</given-names></name> <name><surname>Doi</surname> <given-names>K</given-names></name> <name><surname>Maekawa</surname> <given-names>C</given-names></name> <name><surname>Kizawa</surname> <given-names>K</given-names></name> <name><surname>Horii</surname> <given-names>A</given-names></name> <name><surname>Kubo</surname> <given-names>T</given-names></name> <etal/></person-group>. <article-title>Meniere's attacks occur in the inner ear with excessive vasopressin type-2 receptors</article-title>. <source>J Neuroendocrinol</source>. (<year>2008</year>) <volume>20</volume>:<fpage>1295</fpage>&#x2013;<lpage>300</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2826.2008.01792.x</pub-id>, PMID: <pub-id pub-id-type="pmid">19094077</pub-id></citation>
</ref>
<ref id="ref36">
<label>36.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maekawa</surname> <given-names>C</given-names></name> <name><surname>Kitahara</surname> <given-names>T</given-names></name> <name><surname>Kizawa</surname> <given-names>K</given-names></name> <name><surname>Okazaki</surname> <given-names>S</given-names></name> <name><surname>Kamakura</surname> <given-names>T</given-names></name> <name><surname>Horii</surname> <given-names>A</given-names></name> <etal/></person-group>. <article-title>Expression and translocation of aquaporin-2 in the endolymphatic sac in patients with Meniere's disease</article-title>. <source>J Neuroendocrinol</source>. (<year>2010</year>) <volume>22</volume>:<fpage>1157</fpage>&#x2013;<lpage>64</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2826.2010.02060.x</pub-id>, PMID: <pub-id pub-id-type="pmid">20722976</pub-id></citation>
</ref>
</ref-list>
</back>
</article>